J0665 HCPCS code: Injection, bupivicaine, not otherwise specified, 0.5 mg
J0665 is the HCPCS Level II code for injection, bupivicaine, not otherwise specified, 0.5 mg. In 2024 Medicare paid an average of $0.01 per service for J0665 across 2,668,741 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume rose 471% from 2023 to 2024 (467,391 to 2,668,741 services). In 2024, about 2,775 clinicians billed Medicare for J0665 for 45,464 beneficiaries; California, New Jersey, North Carolina accounted for 38% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-07-01 |
| Last action effective | 2024-01-01 |
Who bills J0665 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,775 |
| Medicare beneficiaries | 45,464 |
| States with claims | 51 |
| Share of services in top 3 states (California, New Jersey, North Carolina) | 38% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0665, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 467,391 | 14,857 | $0.02 | $0.01 |
| 2024 | 2,668,741 | 45,464 | $0.01 | $0.01 |
States with the most J0665 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 623,751 | $0.01 |
| New Jersey | 194,525 | $0.01 |
| North Carolina | 191,447 | $0.01 |
| Texas | 188,096 | $0.01 |
| Washington | 158,206 | $0.01 |
What changed for J0665
- 2023-07-01: J0665 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0665?
J0665 is the HCPCS Level II code for injection, bupivicaine, not otherwise specified, 0.5 mg. Short descriptor: "Inj, bupivacaine, nos, 0.5mg".
How much does Medicare pay for J0665?
In 2024, the average Medicare payment was $0.01 per service (average allowed $0.01).
Does Medicare cover J0665?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J06 codes
- J0600 — Injection, edetate calcium disodium, up to 1000 mg
- J0601 — Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0602 — Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
- J0603 — Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0604 — Cinacalcet, oral, 1 mg, (for esrd on dialysis)
- J0605 — Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
- J0606 — Injection, etelcalcetide, 0.1 mg
- J0607 — Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
- J0608 — Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
- J0609 — Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
- J0610 — Injection, calcium gluconate (fresenius kabi), per 10 ml
- J0611 — Injection, calcium gluconate (wg critical care), per 10 ml
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0665
- Watch J0665 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0665
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.